ENXTPA:SANPharmaceuticals
Sanofi’s Dupixent Win In Pediatric CSU Adds To Undervalued Story
Sanofi (ENXTPA:SAN) received European Commission approval for Dupixent (dupilumab) in children aged 2 to 11 years with chronic spontaneous urticaria.
The decision expands Dupixent’s EU label beyond adults and adolescents to include a new pediatric population.
The approval is based on a combination of adult, adolescent, and dedicated pediatric study data for CSU.
For investors watching ENXTPA:SAN, this latest approval extends one of Sanofi’s key immunology drugs into a younger age group in a...